News

Anatomy of a molecule:
What makes remdesivir unique?

Experts weigh in on the chemistry of the potential SARS-nCoV-2 antiviral
Laurel Oldach
March 17, 2020

The World Health Organization in late January convened experts to discuss experimental therapeutics for patients with the emerging coronavirus with no name, no vaccine and no treatment. The panel reported that “among the different therapeutic options, remdesivir was considered the most promising candidate.”

Within weeks, a clinical trial of the compound was underway in China. Results are expected in April; in the meantime, the outbreak of SARS-nCoV-2, the virus that causes COVID-19, has become a global pandemic.

Remdesivir is a nucleoside analog, one of the oldest classes of antiviral drugs. It works by blocking the RNA polymerase that coronaviruses and related RNA viruses need to replicate their genomes and proliferate in the host body.

The molecule originally was synthesized as part of a screen for inhibitors of the hepatitis C virus RNA polymerase. Its inventors at Gilead Sciences decided to move forward with a different nucleoside analog compound to treat hepatitis C. But RNA-dependent RNA polymerases are conserved between many viruses. Experiments in vitro, in cell culture and in animal models have shown that remdesivir has broad-spectrum activity against RNA viruses, including filoviruses (like the one that causes Ebola) and coronaviruses.

Remdesivir resembles the RNA base adenosine, shown here as a monophosphate.

AMP.jpg

The compound and ATP have some important differences, but some features are very similar. ASBMB Today spoke to medicinal chemist Katherine Seley–Radtke at the University of Maryland, Baltimore County, and structural virologist Craig Cameron at the University of North Carolina, Chapel Hill about what makes the molecule interesting. Click on a feature marked in blue to read their remarks.

Enjoy reading ASBMB Today?

Become a member to receive the print edition monthly and the digital edition weekly.

Learn more
Laurel Oldach

Laurel Oldach is a science writer for the ASBMB.

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in Science

Science highlights or most popular articles

Who has the highest risk of long COVID? It’s complicated
News

Who has the highest risk of long COVID? It’s complicated

Sept. 25, 2022

Sex and age may be risk factors, but researchers are probably missing many others.

Not so silent after all?
Feature

Not so silent after all?

Sept. 23, 2022

Scientists debate synonymous codons’ biological effects.

Shining lights on the cell
Annual Meeting

Shining lights on the cell

Sept. 23, 2022

This symposium, Cell Signaling — New Tools and Emerging Concepts, will be part of #DiscoverBMB 2023 in March.

From the journals: JLR
Journal News

From the journals: JLR

Sept. 23, 2022

A new way to accelerate wound healing. How pasteurization affects enzymes in human milk. Read about papers on these topics recently published in the Journal of Lipid Research.

Microbial engines of global change
Annual Meeting

Microbial engines of global change

Sept. 22, 2022

This symposium, Biochemistry of Elemental Cycling, will be part of #DiscoverBMB 2023 in March.

Control our thoughts and better science will follow
Annual Meeting

Control our thoughts and better science will follow

Sept. 22, 2022

This symposium, Bias In, Bias Out in Data Science, will be part of #DiscoverBMB 2023 in March.